Botanix Pharmaceuticals (ASX:BOT) Debt-to-Asset : 0.24 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Botanix Pharmaceuticals Debt-to-Asset?

Botanix Pharmaceuticals ASX:BOT Debt-to-Asset is 0.24 as of Jun. 2026. The stock has 5 warning signs investors should review.

Botanix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$14.29 Mil. Botanix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$11.48 Mil. Botanix Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was A$105.98 Mil. Botanix Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2026 was 0.24.

Botanix Pharmaceuticals  (ASX:BOT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Botanix Pharmaceuticals Debt-to-Asset Related Terms

Botanix Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Botanix Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals Debt-to-Asset Chart

Botanix Pharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.25 0.24

Botanix Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.25 0.31 0.24

ASX:BOT vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Botanix Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's Debt-to-Asset falls into.


Botanix Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Botanix Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(14.292 + 11.475) / 105.975
=0.24

Botanix Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(14.292 + 11.475) / 105.975
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.24 mean?
Botanix Pharmaceuticals (ASX:BOT) has a Debt-to-Asset of 0.24 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Botanix Pharmaceuticals and its competitors.
Is Botanix Pharmaceuticals' Debt-to-Asset too high?
Botanix Pharmaceuticals' current Debt-to-Asset is 0.24.
How does Botanix Pharmaceuticals' Debt-to-Asset compare to VRTX and REGN?
Botanix Pharmaceuticals' Debt-to-Asset of 0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Botanix Pharmaceuticals and its competitors. Botanix Pharmaceuticals's current Debt-to-Asset is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (ASX:BOT) has a current Debt-to-Asset of 0.24. The current Debt-to-Asset is 0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Botanix Pharmaceuticals (ASX:BOT), the current Debt-to-Asset is 0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Other Exchanges BXPHF:USA
Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.